MAPP BIOPHARMACEUTICAL, INC. — Department of Defense SBIR Phase I: A14-044
MAPP BIOPHARMACEUTICAL, INC. — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $149,877. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code A14-044 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $149,877
- Agency
- Department of Defense · Army
- Program / Phase
- SBIR · Phase I
- Topic
- A14-044
- Solicitation
- 2014.1
- NAICS
- —
- Place of performance
- CA
- Period
- 2014-12-11 → 2016-05-26
Description
Ricin is a category B toxin due to its ease of acquisition, dissemination, and the high potential for morbidity and mortality after exposure. There are currently no methods of preventing or treating ricin exposurethis represents a major unmet need for protection of civilians and warfighters. Because of their excellent safety profile and efficacy, mAbs are a rapidly growing class of therapeutic drugs with a regulatory track record superior to small molecules.The Mapp team, in collaboration with Dr. Nicholas Mantis (Wadsworth Institute, Albany, NY) has identified a highly potent humanized anti-ricin mAb, hPB10. The potency of this mAb is superior to any mAb previously described. In this work effort we propose to increase the serum-half life of hPB10 and establish proof-of-concept in rodent models with a long range objective of developing a safe, effective and long-acting mAb (> 6 months of protection from a single dose) product for ricin intoxication.The envisioned injectable product will be for use in humans both prior to (e.g. by first responders or military personnel entering a contaminated zone) and/or after ricin exposure.